מיפג'ין

Riik: Iisrael

keel: heebrea

Allikas: Ministry of Health

Osta kohe

Infovoldik Infovoldik (PIL)
15-08-2022

Toimeaine:

MIFEPRISTONE

Saadav alates:

A. LAPIDOT PHARMACEUTICALS, LTD

ATC kood:

G03XB01

Ravimvorm:

טבליה

Koostis:

MIFEPRISTONE 200 MG

Manustamisviis:

פומי

Retsepti tüüp:

מרשם נדרש

Valmistatud:

EXELGYNE LABORATORIES, FRANCE

Terapeutiline rühm:

MIFEPRISTONE

Terapeutiline ala:

MIFEPRISTONE

Näidustused:

Medical alternative to uterine suction for termination of intra-utrerine Pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after Mifegyne intake. Under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

Loa andmise kuupäev:

2014-07-31

Dokumendid teistes keeltes

Infovoldik Infovoldik inglise 25-07-2022
Toote omadused Toote omadused inglise 25-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande inglise 11-10-2022
Infovoldik Infovoldik araabia 25-07-2022

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu